8-K: Alnylam Soars on Q3 Results, Raises 2025 Revenue Guidance

Alnylam Pharmaceuticals reported strong third-quarter 2025 financial results, driven by significant growth in its TTR franchise, leading to an upward revision of its full-year revenue guidance.

Summary

• Total Net Product Revenues for Q3 2025 reached $851 million, representing a 103% increase compared to Q3 2024.
• Total TTR Net Product Revenues (AMVUTTRA & ONPATTRO) were $724 million, a 135% growth over Q3 2024, primarily driven by AMVUTTRA.
• AMVUTTRA global net product revenues were $685 million, while ONPATTRO revenues were $39 million.
• ATTR-CM patient demand for AMVUTTRA approximately doubled in the third quarter compared to the second quarter of 2025.
• Total Rare Net Product Revenues (GIVLAARI & OXLUMO) amounted to $127 million, showing a 14% growth compared to Q3 2024.
• Net revenues from collaborations increased, primarily due to a $300 million milestone from Roche associated with the ZENITH Phase 3 trial.
• Royalty revenue grew by 98% to $46.2 million, driven by increased global net sales of Leqvio by Novartis.
• GAAP Net income for Q3 2025 was $251.1 million ($1.91 basic EPS), a significant improvement from a net loss of $(111.6) million ($(0.87) basic EPS) in Q3 2024.
• Non-GAAP Net income for Q3 2025 was $396.2 million ($3.01 basic EPS), compared to a net loss of $(64.2) million ($(0.50) basic EPS) in Q3 2024.
• Cash, cash equivalents, and marketable securities stood at $2.7 billion as of September 30, 2025, a decrease from $2.9 billion as of June 30, 2025, primarily due to convertible note repurchases.
• Full-year 2025 guidance for Total TTR net product revenues was raised to $2,475 million $2,525 million (from $2,175 million $2,275 million).
• Full-year 2025 guidance for Total net product revenues was raised to $2,950 million $3,050 million (from $2,650 million $2,800 million), representing a $275 million / 10% increase at the midpoint.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong financial results, significantly raised its full-year revenue guidance, and made substantial progress in its clinical pipeline, indicating robust operational performance and positive future prospects despite some increased expenses and a regulatory subpoena.

Positives

• Achieved strong Q3 2025 total net product revenue growth of 103% to $851 million.
• Reported exceptional TTR franchise growth of 135% to $724 million, primarily driven by AMVUTTRA.
• AMVUTTRA ATTR-CM patient demand approximately doubled quarter-over-quarter, demonstrating sustained growth momentum and broad uptake.
• Raised full-year 2025 guidance for Total TTR net product revenues to $2,475 million $2,525 million.
• Raised full-year 2025 guidance for Total net product revenues to $2,950 million $3,050 million, a $275 million / 10% increase at the midpoint.
• Recognized significant milestone revenue of $300 million under the collaboration with Roche for the ZENITH Phase 3 trial.
• Presented new data from the HELIOS-B Phase 3 study demonstrating vutrisiran's long-term cardiovascular benefit and lower rates of gastrointestinal events in ATTR-CM.
• Initiated two new Phase 3 trials: ZENITH for zilebesiran in hypertension and TRITON-PN for nucresiran in hATTR-PN.
• Partner Regeneron Pharmaceuticals announced positive results from the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis.
• Achieved GAAP net income of $251.1 million in Q3 2025, a significant turnaround from a net loss in Q3 2024.

Negatives

• ONPATTRO net product revenues decreased by 22% to $39 million, primarily due to patient switches to AMVUTTRA.
• Cash, cash equivalents, and marketable securities decreased to $2.7 billion from $2.9 billion in Q2 2025, primarily driven by the partial repurchase of convertible senior notes.
• GAAP Research and development expenses increased by 32% to $358.8 million, primarily due to increased clinical trial expenses for new Phase 3 trials.
• GAAP Selling, general and administrative expenses increased by 46% to $322.1 million, mainly due to higher employee compensation and increased marketing investment for the AMVUTTRA launch.
• Incurred a loss related to convertible debt of $39.1 million, representing an inducement expense on the partial repurchase of 1.00% convertible senior notes due 2027.
• Recorded a charge of $65 million associated with the change in fair value of the development derivative liability.

Risks

• Ability to successfully execute on the Alnylam P5x25 strategy.
• Ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
• Pre-clinical and clinical results for product candidates, including zilebesiran, nucresiran, and mivelsiran, may not be favorable.
• Actions or advice of regulatory agencies and the ability to obtain and maintain regulatory approval for product candidates, as well as favorable pricing and reimbursement.
• Successfully launching, marketing, and selling approved products globally.
• Delays, interruptions, or failures in the manufacture and supply of product candidates or marketed products.
• Obtaining, maintaining, and protecting intellectual property.
• Ability to manage growth and operating expenses through disciplined investment in operations and achieve a self-sustainable financial profile without the need for future equity financing.
• Ability to maintain strategic business collaborations.
• Dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron.
• Outcome of litigation.
• Risk of future government investigations, including the subpoena from the U.S. Attorney's Office for the District of Massachusetts regarding government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI.
• Unexpected expenditures.

Future Outlook

Alnylam expects continued strong growth, particularly from its TTR franchise, and is advancing multiple pipeline programs into late-stage development, including two new Phase 3 trials for zilebesiran in hypertension and nucresiran in hATTR-PN. The company aims to achieve its Alnylam P5x25 goals, establishing itself as a top-tier profitable biotech company delivering transformational innovation.

Management Comments

• "Alnylam's impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients around the world." Yvonne Greenstreet, M.D., Chief Executive Officer.
• "AMVUTTRA's robust clinical profile, convenient quarterly administration, and broad payer coverage all continue to drive this encouraging pace of uptake and further position Alnylam as a leader in TTR." Yvonne Greenstreet, M.D., Chief Executive Officer.
• "Based on the ATTR-CM launch trajectory, we are again raising our guidance and expect total net product revenues of $2.95 billion to $3.05 billion for 2025." Yvonne Greenstreet, M.D., Chief Executive Officer.
• "As we near the end of our Alnylam P5x25 era, we couldn't be more excited by the progress we've made establishing Alnylam as a top-tier profitable biotech company delivering transformational innovation to patients, and building a strong foundation for our next phase of growth." Yvonne Greenstreet, M.D., Chief Executive Officer.

Industry Context

Alnylam continues to solidify its leadership in RNAi therapeutics, particularly in rare diseases like ATTR amyloidosis. The strong performance of AMVUTTRA and the advancement of new Phase 3 programs, including zilebesiran for hypertension, demonstrate the company's ability to expand its therapeutic reach beyond rare diseases into larger markets, positioning it competitively against other biotech and pharmaceutical companies developing novel gene-silencing or cardiovascular treatments.

Comparison to Industry Standards

• The 103% growth in total net product revenues and 135% growth in TTR net product revenues significantly outperform typical industry growth rates for established pharmaceutical products, especially for a company of Alnylam's size.
• The rapid uptake of AMVUTTRA, with patient demand approximately doubling quarter-over-quarter in ATTR-CM, indicates strong market acceptance and competitive advantage, potentially surpassing initial launch trajectories of similar rare disease therapies.
• The successful advancement of two new Phase 3 trials (ZENITH for zilebesiran and TRITON-PN for nucresiran) and positive Phase 3 results for cemdisiran (partnered with Regeneron) demonstrate a robust and productive R&D pipeline, which is a key differentiator in the highly competitive biotech sector.
• The achievement of GAAP net income of $251.1 million in Q3 2025, a turnaround from a loss in the prior year, positions Alnylam favorably compared to many development-stage or early-commercial biotech companies that often operate at a loss.

Management Changes

Legal Proceedings

• Received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents pertaining to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI, including certain fee and discount arrangements with distributors.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and pipeline advancements, potentially leading to increased share value.
• Patients: Continued access to innovative RNAi therapeutics like AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, with new therapies in development for various conditions.
• Employees: Higher employee compensation costs and increased headcount indicate growth and potential opportunities.
• Partners (Roche, Regeneron, Novartis, Sanofi): Strong collaboration revenues and positive clinical trial results for partnered programs reinforce successful partnerships.
• Regulatory Authorities: Engagement with the U.S. Attorney's Office regarding a subpoena on price reporting.

Next Steps

• Present new results from the HELIOS-B Phase 3 trial on the impact of vutrisiran on cardiac MRI in patients with ATTR-CM at the American Heart Association Scientific Sessions 2025 (November 7-10, 2025).
• Initiate a Phase 2 trial of mivelsiran in patients with Alzheimer's disease in Q4 2025.
• Regeneron Pharmaceuticals plans a U.S. regulatory submission for cemdisiran monotherapy in the first quarter of 2026.
• Topline results for the TRITON-PN Phase 3 trial of nucresiran are expected in 2028.

Key Dates

Recommendation

The company delivered exceptional Q3 2025 financial results, significantly exceeding expectations with 103% total net product revenue growth and a 135% increase in its core TTR franchise. The substantial upward revision of full-year 2025 revenue guidance by 10% at the midpoint, coupled with the achievement of GAAP net income, demonstrates robust commercial execution and strong underlying business momentum. Furthermore, the advancement of two new Phase 3 trials and positive data from existing programs highlight a productive and expanding pipeline. While there is a regulatory subpoena, the overall financial and operational performance indicates a strong growth trajectory and solidifies its leadership in RNAi therapeutics, making it an attractive investment.

Keywords

RNAi therapeutics, Alnylam, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, ATTR-CM, hATTR-PN, hypertension, zilebesiran, nucresiran, vutrisiran, pharmaceuticals, biotechnology, Q3 earnings, financial results, guidance update, clinical trials, drug development